Stock Ratings | HC Wainwright raised its price target for Autolus Therapeutics (AUTL) to $10, representing a potential upside of 528.93%; Morgan Stanley raised its price target for Nebius Group (NBIS) to $144.
AUTOLUS THERAPEUTICS LTD AUTL | 0.00 | |
Rezolute RZLT | 0.00 | |
Precigen Inc PGEN | 0.00 | |
Kalaris Therapeutics, Inc. KLRS | 0.00 | |
Aprea Therapeutics APRE | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
HC Wainwright & Co.: Maintaining a "buy" rating on AUTOLUS THERAPEUTICS LTD(AUTL.US) stock, with a price target raised from $9 to $10.
Maxim Group: Maintaining a "buy" rating on Rezolute ( Rezolute(RZLT.US) ) stock, while raising the price target from $4 to $10.
Citizens: Maintaining Precigen's ( Precigen(PGEN.US) ) rating at "Outperforming the Market," while raising the price target from $9 to $11.
Wedbush: Kalaris Therapeutics ( Kalaris(KLRS.US) ) initial rating at "outperforms market", with a price target of $17.
Wedbush: Maintaining Aprea Therapeutics(APRE.US) ' rating at "Outperform Market", while lowering the price target from $7 to $6.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| AUTOLUS THERAPEUTICS LTD(AUTL.US) | to lift | $10.0 | $1.59 | 528.93% | HC Wainwright & Co. |
| Rezolute(RZLT.US) | to lift | $10.0 | $3.4 | 194.12% | Maxim Group |
| Precigen(PGEN.US) | to lift | $11.0 | $4.6 | 139.13% | Citizens |
| Precigen(PGEN.US) | to lift | $11.0 | $4.6 | 139.13% | HC Wainwright & Co. |
| Avalo Therapeutics Inc(AVTX.US) | to lift | $45.0 | $19.01 | 136.72% | Mizuho |
| Kalaris(KLRS.US) | Initial classification | $17.0 | $5.22 | 225.67% | Wedbush |
| Aprea Therapeutics(APRE.US) | cut | $6.0 | $0.941 | 537.62% | Wedbush |
| UpStream Bio(UPB.US) | cut | $50.0 | $8.79 | 468.83% | Mizuho |
| MDxHealth S.A.(MDXH.US) | cut | $5.0 | $0.9847 | 407.77% | Lake Street |
| Protara Therapeutics, Inc.(TARA.US) | cut | $26.0 | $5.3 | 390.57% | JP Morgan |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Evercore ISI Group: Maintaining Apple's Apple Inc.(AAPL.US) rating at "Outperforming the Market," while raising the price target from $330 to $365.
Tigress Financial: Maintaining a "Strong Buy" rating on Apple Apple Inc.(AAPL.US) ) stock, while raising its price target from $305 to $375.
Wells Fargo: Maintaining an "overweight" rating on Broadcom Broadcom Limited(AVGO.US) ), while raising its price target from $430 to $545.
Citigroup: Maintaining a "buy" rating on CoreWeave ( CoreWeave(CRWV.US) ), while raising the price target from $155 to $158.
Morgan Stanley: Maintaining an "overweight" rating on Cisco Systems Cisco Systems, Inc.(CSCO.US) stock, while raising the price target from $91 to $120.
Piper Sandler: Maintaining a "neutral" rating on Cisco Systems Cisco Systems, Inc.(CSCO.US) stock, while raising the price target from $86 to $132.
Citigroup: Maintaining a "buy" rating on Dell Dell Technologies, Inc. Class C(DELL.US) stock, while raising its price target from $235 to $290.
Morgan Stanley: Maintaining the rating of Nebius Group ( NEBIUS(NBIS.US) ) at "Market Weight in Match," while raising the price target from $126 to $144.
DA Davidson: Maintaining a "buy" rating on Nebius Group ( NEBIUS(NBIS.US) ), with a price target raised from $200 to $250.
First Coverage
Stephens & Co.: Initial rating for Academy Sports ( Academy Sports and Outdoors, Inc.(ASO.US) ) stock at "overweight", with a target price of $78.
Jefferies: Initial rating for Cipher Digital ( Cipher Mining(CIFR.US) ) stock at "Buy", with a target price of $32.
Jefferies: Initial rating for HUT 8 ( HUT 8(HUT.US) ) stock at "Buy", with a target price of $156.
Wedbush: Kalaris Therapeutics ( Kalaris(KLRS.US) ) initial rating at "outperforms market", with a price target of $17.
Roth Capital: Initial rating for Suncrete ( Suncrete, Inc. Class A(RMIX.US) ) stock at "Buy", with a target price of $21.
reduction
Wells Fargo: Maintaining an "overweight" rating on Home Depot Home Depot, Inc.(HD.US) stock, while lowering its price target from $420 to $375.
Bernstein: Maintaining a "Market Match" rating for Home Depot Home Depot, Inc.(HD.US) stock, while lowering the price target from $390 to $365.
Stephens & Co.: Maintaining an "overweight" rating on QXO ( QXO, Inc.(QXO.US) ) stock, while lowering the price target from $29 to $26.
Needham: Maintaining a "buy" rating on Wix.com Wix.com Ltd.(WIX.US) stock, while lowering the price target from $115 to $80.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.